上一節(jié)課程，劉紅兵老師為我們介紹了MPE的診斷和傳統(tǒng)治療方法，本次課程將繼續(xù)同一講題，介紹MPE的細(xì)胞因子藥物治療進(jìn)展。

近年來生物免疫制劑發(fā)展較為迅速，臨床中應(yīng)用較為廣泛。它既能參與免疫調(diào)節(jié)，也能起到抗腫瘤的作用。此類藥物一般患者可以耐受，毒副作用較小，減少了骨髓抑制及消化道反應(yīng)的發(fā)生。腫瘤壞死因子、血管內(nèi)皮生長因子等藥物都展現(xiàn)出不錯(cuò)的臨床結(jié)果，多個(gè)研究已證實(shí)其在MPE中的應(yīng)用價(jià)值。然而，未來仍有許多有待繼續(xù)研究的課題在等待著我們。

本節(jié)課程，劉紅兵老師深入講解這些潛力藥物的機(jī)制和臨床進(jìn)展，并且在課程的最后還有ATS/STS/STF臨床實(shí)踐指南的重點(diǎn)解讀，一起來學(xué)習(xí)吧。

內(nèi)容提要：

1. 腫瘤壞死因子（TNF）治療MPE

2. VEGF抗體治療MPE

3. ATS/STS/STR 惡性胸腔積液臨床實(shí)踐指南重點(diǎn)解讀

(最下方有課程中涉及的文獻(xiàn)信息）

請?zhí)砑诱n程助手（微信號(hào)：Rachelsunyue）為好友，邀您加入“惡性胸腹水處理微信交流群”。

文獻(xiàn)信息：

1. 惡性胸腔積液診斷與治療專家共識(shí)，中華內(nèi)科雜志，2014，53(3):252-256

2. 張玉, 等. 惡性胸腔積液綜合治療進(jìn)展[J]. 現(xiàn)代生物醫(yī)學(xué)進(jìn)展, 2012,12(17):3358-3361.

3.注射用重組改構(gòu)人腫瘤壞死因子治療國人惡性胸、腹腔積液的前瞻性多中心臨床研究[J]. 臨床腫瘤學(xué)雜志, 2016, 21(7).

4. 晚期非小細(xì)胞肺癌抗血管生成藥物治療中國呼吸領(lǐng)域?qū)＜夜沧R(shí)，中華結(jié)核和呼吸雜志.2016,39(11):839-849.

5. 秦叔逵,等.腔內(nèi)應(yīng)用重組人血管內(nèi)皮抑制素和/或順鉑治療惡性胸腹腔積液的前瞻性、隨機(jī)對照、全國多中心Ⅲ期臨床研究[J].臨床腫瘤學(xué)雜志,2017,22(3):193-202.

6. Frances Balkwill. Tumour necrosis factor and cancer. Nature reviews cancer, 9, 2009:361-371

7. Balkwill, F., Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9 (5), 361-71.

8. Du, N, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer?mediated malignant pleural effusion. Oncol Rep 2013, 29 (6), 2332-40.

9. Feller-Kopman, D. J, et al. A. A., Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med 2018, 198 (7), 839-849.

10. Ishii, H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004, 45 (3), 325-37.

5. Kitamura, K, et al. Yoshimura, A.; Gemma, A., Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol 2013, 71 (2), 457-61.

6. Lejeune, F. J, Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002, 110 (4), 433-5.

7. Limaverde-Sousa, G, et al. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014, 40 (4), 548-57.

8. Ma, X, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One 2012, 7 (12), e53449.

9. Spella, M, et al.  Switching off malignant pleural effusion formation-fantasy or future? J Thorac Dis 2015, 7 (6), 1009-20.

10. Tamiya, M, et al. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 2013, 30 (3), 676.

11. Yano, S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000, 157 (6), 1893-903.